Aachen

• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-501621-20-00 5 2023-10-02 Prurigo Nodularis
• A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno … Ended
  2022-501885-24-00 5 2023-09-20 Contrast enhancement in magnetic resonance imaging for assessment of n
• HU-F-AIM - A prospective, interventional clinical study to evaluate hydroxyurea (HU) resistance in patients with polycythaemia vera who meet … Ended
  2022-502338-20-00 6 2023-07-28 Polycythemia vera
• A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgest … Ended
  2022-502024-51-00 5 2023-07-12 Prevention of pregnancy
• A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS90 … Ended
  2022-501190-39-01 3 2023-05-15 Paroxysmal nocturnal hemoglobinuria
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th … Ended
  2022-500121-33-01 5 2023-05-08 Anti-GBM antibody disease (Goodpasture disease)
• A study to find out if daridorexant is safe and efficacious to treat insomnia in patients with insomnia and comorbid nocturia Ended
  2022-501246-30-00 6 2023-03-08 Insomnia Disorder
• A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous … Ended
  2024-516300-41-00 5 2023-03-07 Multiple Myeloma
• Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af … Ended
  2024-510590-14-00 5 2023-03-03 multiple myeloma
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• VItamin C in Thermal injuRY: The VICToRY Trial A phase III multi-center randomized trial Ended
  2023-504772-21-00 4 2022-11-22 Severely burned patients
• Study to evaluate the efficacy and safety of fedratinib in combination with CC-486 in patients suffering from myelofibrosis in acute phase. Ended
  2024-519227-22-00 9 2022-11-03 Myeloproliferative neoplasm in accelerated phase (MPN-AP)
• Early Reperfusion Therapy for Recovery of Vision in Acute Central Retinal Artery Occlusion Ended
  2023-507388-21-00 5 2022-09-08 Acute non-arteritic central retinal artery occlusion (CRAO)
• Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) th … Ended
  2024-515485-14-00 5 2022-07-07 Acute major bleeding in patients receiving DOAC therapy with factor Xa
• Inducta Ended
  2023-509837-37-00 4 2022-02-25 Patients with locally advanced T4 high risk prostate cancer
• GRAPPA Ended
  2023-510441-24-00 5 2022-01-28 Graft Vs Host Disease Peripheral Blood Stem Cell Transplantation AML M
• The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic … Ended
  2024-517251-12-00 5 2021-11-02 Recurrent or metastatic head and neck squamous cell carcinoma
• Study to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of therapy-resistant chronic venous ulcer (CVU) Ended
  2023-510162-27-00 4 2021-08-18 Chronic venous ulcers (CVU)
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended
  2023-506919-18-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
• A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab … Ended
  2023-507317-10-00 5 2021-05-10 Locally advanced, unresectable, or metastatic non small cell lung canc
• Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffus … Ended
  2023-508259-38-00 5 2021-04-29 Adult patients with relapsed or primary refractory DLBCL
• Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ustek … Ended
  2023-504978-38-00 5 2021-03-16 Moderately to Severely Active Crohn's Disease
• A Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ust … Ended
  2023-504977-19-00 5 2021-03-15 Moderately to Severely Active Ulcerative Colitis
• Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended
  2024-511067-29-00 5 2021-01-25 IgA Nephropathy

Showing 241–264 of 279 trials